Refine by
In Vitro Study Suppliers Serving Kuwait
45 companies found
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Hydroxyurea is a cell apoptosis inducer that inhibit DNA synthesis through inhibition of ribonucleotide reductase. Hydroxyurea shows anti-orthopoxvirus ...
based inPipersville, PENNSYLVANIA (USA)
LAMPIRE specializes in custom polyclonal & monoclonal antibody development, secondary antibodies, IgGs, BSA, animal blood, tissues & organs, normal & disease state human serums & plasmas, cell media, OMNI C3 cell culture bags & contract ...
based inHanden, SWEDEN
BioThema developes, produces and sells reagents and kits for measuring ATP by the firefly luciferase reaction. Applications include rapid cell counting, cell proliferation and cytotoxicity, immunoassays, monitoring enzymes and metabolites, reporter ...
based inBudapest, HUNGARY
CycloLab is a worldwide recognized and all-around cyclodextrin research and development company, having the longest tradition and broadest circle of customers. Since 1972, a staff of internationally acknowledged experts have been working in the ...
Incorporating new APIs into final products might prove challenging: stability, solubility, bioavailability, etc. issues may arise. Several attributes of these substances can be favorably altered by cyclodextrins. Cyclodextrins themselves can also ...
based inDerio, SPAIN
Innoprot is a company specializing in the development and provision of high-quality cell lines and assays for use in research and drug discovery. They offer a wide array of G protein-coupled receptor (GPCR) cell lines, which are essential for ...
based inNess Ziona, ISRAEL
BiomX is developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as cystic fibrosis, inflammatory bowel disease, atopic ...
We are developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa (P. aeruginosa) respiratory infections, a main contributor to morbidity and mortality in this disease. Phase 1b/2a clinical study in CF patients is composed ...
based inGuildford, UNITED KINGDOM
Futura Medical is a pharmaceutical company developing a portfolio of innovative products based on our proprietary, transdermal DermaSys technology. Futura Medical is an innovative R&D company with a pipeline of products in late stage development. ...
Scientific advisory meeting held with MHRA confirming the need of a Phase 3 study to support the improved skin permeation including potential superior efficacy claims. Exploring the feasibility of a clinical study to satisfy the Phase 3 requirements ...
based inLargo, FLORIDA (USA)
CONMED is a global medical technology company that specializes in the development and sale of surgical and patient monitoring products and services that allow our physician customers to deliver high quality care and as a result, enhanced clinical ...
With strong fixation, less bone removal and a simple, self-punching technique, the Y-Knot® RC helps overcome the trade-offs of other rotator cuff fixation methods. The first self-punching all-suture anchor available, Y-Knot® RC anchors can ...
based inMississauga, ONTARIO (CANADA)
Covalon Technologies Ltd. (Covalon) develops and commercializes proprietary technologies for major medical device manufacturers. Our partners include the top medical device companies, leaders in urology, wound care, vascular access, venture capital, ...
based inCopenhagen, DENMARK
Cmbio specializes in advancements in microbiome science and multi-omics research, primarily focused on human, animal, and planetary health. With a team of over 100 experts in microbiology, bioinformatics, metabolomics, molecular biology, and data ...
based inTrabzon, TURKEY
Dogsan, the first suture manufacturer of Turkey, Middle East and Balkan states, is founded in 1970 and have a long history in suture manufacturing. Competing with the global brands, Dogsan have gained its power from 45 year of expertise, almost 50 ...
PEGELAK sutures are synthetic absorbable sterile surgical sutures which are flexible strands composed of a copolymer prepared and synthesized from 90 percent glycolide and 10 percent L-lactide (derived from glycolic and lactic acids) and are ...
based inDiepenbeek, BELGIUM
Founded in 2012, InnoSer is an innovative and dynamic contract research organization supporting preclinical development of drugs from its facilities in Belgium and the Netherlands. InnoSer supports its customers in the critical steps of their drug ...
We have specialized facilities for in vitro and in vivo offerings. Our established scientific experience and customized, collaborative approach make InnoSer the ideal ally for your company to achieve meaningful, high-quality and fast results. ...
based inMilpitas, CALIFORNIA (USA)
BioVision, Inc., is a privately held Life Science company headquartered in the beautiful San Francisco Bay Area. BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other ...
based inCorona, CALIFORNIA (USA)
For over 20 years, United Endoscopy has been a leader in providing state-of-the-art refurbished medical equipment and advanced equipment repair to its customers worldwide. Since its founding in 1996 by Jeremy Cooper, United Endoscopy has ...
based inSunnyvale, CALIFORNIA (USA)
JSR Life Sciences brings together the deep biochemical knowledge and understanding of human disease, expertise in drug discovery and development, and access to capital into a single, integrated framework that creates value for our customers. JSR ...
based inYuseong-gu, SOUTH KOREA
We strive to become a leading biotech company that contributes to human health and well-being by providing innovative therapeutic antibodies to patients with unmet medical needs. We have been committed to developing novel antibody therapeutics since ...
PMC-402 is a monoclonal antibody that targets the human TIE2 that regulated activation, proliferation, and repolarization of Tie2 expressing macrophages, resulting in T cell activation. It binds to TIE2 expressing macrophages that activate T cells ...
based inVancouver, BRITISH COLUMBIA (CANADA)
InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
TP-0184 is an investigational inhibitor of activin receptor-like kinase 2 (ALK2) and ALK5 (also known as TGFβR1). This bimodal inhibitor is believed to downregulate multiple TGF-β superfamily signaling pathways and has shown antitumor ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
We are developing CYNK-101 as a combination treatment for multiple cancer indications. CYNK-101 is manufactured from a specific type of immune cell, NK cells, that we extract from postpartum placentas and then genetically engineer to increase cell ...
based inBrighton, UNITED KINGDOM
Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention. We have two exciting late-stage clinical assets and a range of earlier research programmes. Our ...
The XF drug platform has a novel, ultra-rapid mechanism that reduces the chance of bacteria becoming resistant to its action. Destiny Pharma’s XF platform has advantages over traditional antibiotics. ...